C. Yee

发表

Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin

C. Johnson, S. Almo, Lan Hua, 2017, ACS medicinal chemistry letters.

Alpha-1-Antitrypsin and a Broad Spectrum Metalloprotease Inhibitor, RS113456, Have Similar Acute Anti-Inflammatory Effects

Li Zhang, A. Karsan, A. Churg, 2001, Laboratory Investigation.

Discovery of a series of novel 5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers, as potent JAK3 kinase inhibitors.

Johannes C. Hermann, A. Kuglstatter, M. Vu, 2013, Bioorganic & medicinal chemistry letters.

Transport of levovirin prodrugs in the human intestinal Caco-2 cell line.

Fujun Li, Lei Hong, T. Alfredson, 2006, Journal of pharmaceutical sciences.

Using ovality to predict nonmutagenic, orally efficacious pyridazine amides as cell specific spleen tyrosine kinase inhibitors.

Johannes C. Hermann, C. Lukacs, A. Kuglstatter, 2014, Journal of medicinal chemistry.

Cloning and Expression of a 5‐Hydroxytryptamine7 Receptor Positively Coupled to Adenylyl Cyclase

A. Tsou, R. Alvarez, R. Eglen, 1994, Journal of neurochemistry.

Strategic use of conformational bias and structure based design to identify potent JAK3 inhibitors with improved selectivity against the JAK family and the kinome.

Johannes C. Hermann, John Menke, Sue Jin, 2013, Bioorganic & medicinal chemistry letters.

Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors.

H. Sham, J. Partridge, A. Dementiev, 2018, Blood advances.

Non-nucleoside inhibitors of HCV polymerase NS5B. Part 4: structure-based design, synthesis, and biological evaluation of benzo[d]isothiazole-1,1-dioxides.

April Wong, J. E. Robinson, Jim Li, 2009, Bioorganic & medicinal chemistry letters.

3-Amido pyrrolopyrazine JAK kinase inhibitors: development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models.

Alam Jahangir, Johannes C. Hermann, Seth Harris, 2013, Journal of medicinal chemistry.

Mutations in the B2 Bradykinin Receptor Reveal a Different Pattern of Contacts for Peptidic Agonists and Peptidic Antagonists*

K. Jarnagin, S. Bhakta, Aaron B. Miller, 1996, The Journal of Biological Chemistry.

Cyclic amide bioisosterism: strategic application to the design and synthesis of HCV NS5B polymerase inhibitors.

Amy D. Fung, N. Arora, S. Harris, 2010, Bioorganic & medicinal chemistry letters.

Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agents.

T. Mirzadegan, K. A. Walker, R. Hendricks, 2004, Journal of medicinal chemistry.

Matrix metalloproteinase inhibition limits arterial enlargements in a rodent arteriovenous fistula model.

C. Zarins, R. Dalman, T. Abbruzzese, 1998, Surgery.

Bradykinin-B2 receptors in humans and rats: cDNA structures, gene structures, possible alternative splicing, and homology searching for subtypes.

K. Jarnagin, C. Bach, W. Müller-Esterl, 1994, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

Non-nucleoside inhibitors of HCV polymerase NS5B. Part 3: synthesis and optimization studies of benzothiazine-substituted tetramic acids.

J. E. Robinson, J. Blake, C. Oshiro, 2009, Bioorganic & medicinal chemistry letters.

Non-nucleoside inhibitors of HCV polymerase NS5B. Part 2: Synthesis and structure-activity relationships of benzothiazine-substituted quinolinediones.

J. E. Robinson, J. Blake, C. Oshiro, 2009, Bioorganic & medicinal chemistry letters.